Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of astegolimab for long-term safety in chronic obstructive pulmonary disease
PACTR202407572301048Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Primary endpoint: Long-term safety of astegolimab. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on PACTR202407572301048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407572301048.